phmacao login

Sake japonés ingresa a la lista del Patrimonio Cultural Inmaterial de la UNESCOBy David Morgan WASHINGTON (Reuters) -Republicans in the U.S. Congress are discussing a two-step plan to push ahead on President-elect Donald Trump's agenda when they take control of both chambers next year, potentially starting with border security, energy and defense before turning to tax cuts. Incoming Senate Majority Leader John Thune, whose Republicans will hold a 53-47 majority, laid out a plan in a closed-door party meeting on Tuesday that included a call from Trump himself. It aims to use a parliamentary maneuver to bypass the chamber's "filibuster" rule that requires 60 senators to agree to advance most legislation. According to the Senate plan, the first bill would focus on Trump's agenda for border security, energy deregulation and defense spending, while the second would extend tax cuts from the 2017 Tax Cuts and Jobs Act passed during the first Trump presidency, which are due to expire next year. Thune told reporters that the plan amounted to "options, all of which our members are considering." To enact Trump's agenda, the Senate will have to work closely with the president-elect and the House of Representatives, which is expected to have a razor-thin Republican majority. "We were always planning to do reconciliation in two packages. So we're discussing right now how to allocate the various provisions, and we're making those decisions over the next couple of days," said House Speaker Mike Johnson, who joined Senate Republicans at their meeting. "There are different ideas on what to put in the first package and what in the second, and we're trying to build consensus around those ideas," Johnson told reporters. The speaker also said that he believes Congress in coming weeks will pursue a continuing resolution, or CR, that would fund federal agencies into March. Current funding is set to expire on Dec. 20. Before moving a first reconciliation bill, the House and Senate will need to agree on a budget resolution to unlock the "reconciliation" tool they plan to use to bypass the filibuster. Aides said senators hope to do that by the end of January and then move quickly to complete the first bill by March 31. "We have the trifecta for two years. About 18 months is all we're really going to have to really get things done," Republican Senator Mike Rounds told reporters. Democrats also leaned heavily on reconciliation to pass legislation when they held control of both chambers during the first two years of President Joe Biden's term. Republican Senator Rand Paul, a fiscal hawk, raised concerns about the plan's cost. "This is not a fiscally conservative notion," Paul said. "So at this point, I'm not for it, unless there are significant spending cuts attached." Extending Trump's tax cuts for individuals and small businesses will add $4 trillion to the current $36 trillion in total U.S. debt over 10 years. Trump also promised voters generous new tax breaks, including ending taxes on Social Security, overtime and tip income and restoring deductions for car loan interest. The tab is likely to reach $7.75 trillion above the CBO baseline over 10 years, according to the Committee for a Responsible Federal Budget, a non-partisan fiscal watchdog group. (Reporting by David Morgan; Editing by Scott Malone, Stephen Coates and Shri Navaratnam) Copyright 2024 Thomson Reuters .None

Pat King found guilty of mischief for role in ‘Freedom Convoy’NEW YORK--(BUSINESS WIRE)--Dec 12, 2024-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer. “Our decision to increase our quarterly dividend underscores our strong financial performance, disciplined execution and our commitment to returning value to our shareholders,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer . Disclosure Notice: The information contained in this release is as of December 12, 2024. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about the Company’s quarterly dividend and capital allocation strategy that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com . Category: Finance View source version on businesswire.com : https://www.businesswire.com/news/home/20241211645444/en/ CONTACT: Media Contact: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226Investor Contact: IR@Pfizer.com +1 (212) 733-4848 KEYWORD: NEW YORK UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY FDA HEALTH PHARMACEUTICAL CLINICAL TRIALS SOURCE: Pfizer Inc Copyright Business Wire 2024. PUB: 12/12/2024 05:25 PM/DISC: 12/12/2024 05:25 PM http://www.businesswire.com/news/home/20241211645444/en

‘World at dawn of third nuclear age’, armed forces chief warns